Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||AB154 + Durvalumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AB154||AB-154|AB 154|Domvanalimab||Immune Checkpoint Inhibitor 151 TIGIT Antibody 17||AB154 (domvanalimab) is a monoclonal antibody that targets T-cell immunoreceptor with Ig and ITIM domains (TIGIT), potentially resulting in enhanced immune response (Cancer Immunol Res 2019;7(2 Suppl):Abstract nr A124).|
|Durvalumab||Imfinzi||MEDI4736||Immune Checkpoint Inhibitor 151 PD-L1/PD-1 antibody 98||Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, in combination with Imjudo (tremelimumab) and platinum-based chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC) without sensitizing EGFR or ALK mutations, in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer, in combination with cisplatin and gemcitabine in patients with locally advanced or metastatic biliary tract cancer, and in combination with Imjudo (tremelimumab) in adult patients with unresectable hepatocellular carcinoma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05211895||Phase III||Durvalumab AB154 + Durvalumab||A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC||Recruiting||USA | ITA | FRA | ESP | DEU | BEL||18|